Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Account Payables (2016 - 2025)

Tandem Diabetes Care's Change in Account Payables history spans 11 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 504.03% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $2.2 million, up 193.1%, while the annual FY2025 figure was $2.2 million, 193.1% up from the prior year.
  • Change in Account Payables reached $5.8 million in Q4 2025 per TNDM's latest filing, up from -$9.3 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $10.5 million in Q1 2021 to a low of -$9.3 million in Q3 2025.
  • Average Change in Account Payables over 3 years is $1.2 million, with a median of -$898000.0 recorded in 2025.
  • The largest YoY upside for Change in Account Payables was 504.03% in 2025 against a maximum downside of 682.06% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $10.5 million in 2021, then plummeted by 113.67% to -$1.4 million in 2024, then soared by 504.03% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Change in Account Payables are $5.8 million (Q4 2025), -$9.3 million (Q3 2025), and -$898000.0 (Q2 2025).